The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.
The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.
The Danaher subsidiary aims to meet clinician needs for flexibility with a range of test size options for its vast installed base.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback